UK announced as global centre of major cardiovascular trial as Novartis opens new HQ in White City, London
Feb 11, 2020
Novartis plans a primary prevention study for inclisiran in the UK, which would see the UK become the trial’s global centre
Coronary heart disease, the most common type of cardiovascular disease, is responsible for around 64,000 deaths in the UK each year1
Announcement made on the same day Novartis formally opens state-of-the-art new UK headquarters in White City, West London
The Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care, to officially open new HQ
London, UK. 14:00 GMT, 11 February 2020 – Novartis today reaffirmed its commitment to the UK as it announced the country will become the global centre of a major new clinical trial to investigate the use of inclisiran in improving cardiovascular outcomes (including heart attack or stroke) by reducing Low Density Lipoprotein Cholesterol (LDL-C). The announcement is made on the same day the company formally opens its new headquarters in White City, London, and pledged to expand its digital Biome programme to the UK.
Novartis is currently planning a primary prevention study with inclisiran in the UK, building on the methods used to recruit 500,000 patients into the UK Biobank2 and to conduct ORION-4, the ongoing study for patients who have already had a heart attack or stroke. This second study would see the UK become the global trial centre. Novartis will work in partnership with the Nuffield Department of Population Health at Oxford University, the NHS and the National Institute for Health Research (NIHR) as part of this programme.
In addition, the innovative collaboration between Novartis and the NHS pioneers a world-first, population health model to a large at-risk patient population with atherosclerotic cardiovascular disease. Following regulatory approval and the National Institute for Health and Care Excellence (NICE) assessment, the proposed population-level agreement would provide access to treatment for secondary prevention ASCVD patients as part of a distribution programme for patients not reaching their LDL-C target on statins alone.
Enabling access to this high-risk population could make a significant contribution towards meeting the NHS long-term commitment3 to prevent 150,000 cardiovascular deaths over 10 years. In addition, it may help to deliver the ambitions of the Government’s Accelerated Access Collaborative4commitment on the variation of uptake to medicines, providing answers as to how innovative medicines can be delivered at scale across the NHS. There is also a proposal to look at manufacturing synergies that could improve oligonucleotide manufacturing scale and efficiency.
“As a company working to improve and extend human life, we’re optimistic about today’s announcement and what this could mean in the ongoing battle against cardiovascular disease—the world’s leading cause of death and disability. We see the UK, with its deep commitment to life sciences, as an attractive place to reimagine medicine,” commented Vas Narasimhan, Chief Executive Officer at Novartis.
“This new trial offers an important opportunity to test the ability of inclisiran to lower the risk of heart disease and stroke in a broad range of people. At the same time, it will demonstrate how a new generation of streamlined trials can provide reliable information about novel treatments for conditions that affect large numbers of NHS patients,” commented Sir John Bell, Regius Professor of Medicine at Oxford University.
Today also sees Novartis formally open their new UK headquarters in White City Place which is quickly becoming home to several pioneering life sciences companies at the forefront of innovation and will bring Novartis in close proximity to Imperial College London’s major new research and innovation campus. In a formal ceremony, the new headquarters will be opened by the Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care, together with Vas Narasimhan, Chief Executive Officer at Novartis, Marie-France Tschudin, President of Novartis Pharmaceuticals and Haseeb Ahmad, Managing Director, UK, Ireland and Nordics, Novartis Pharmaceuticals and Country President, Novartis UK.
“The UK life sciences sector is at a crossroads, with many opportunities available for cutting-edge innovation and partnerships. White City is fast becoming one of the UK’s most exciting new hubs for life sciences, and puts us in the perfect position to continue working with our partners to find new ways to innovate and collaborate to build a healthier tomorrow,” commented Haseeb Ahmad, Managing Director, UK, Ireland and Nordics, Novartis Pharmaceuticals and Country President, Novartis UK.
To coincide with the opening of the new headquarters, Novartis Institutes for BioMedical Research (NIBR) will host a scientific symposium for around 200 UK scientists at the Imperial College London campus in White City. NIBR is the innovation engine of Novartis. It collaborates across scientific and organisational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients. The symposium will give UK scientists the opportunity to learn more about NIBR’s scientific priorities and how they can work with the organisation.
Professor Alice Gast, President of Imperial College London, said “Novartis is a leader in the world of medicines and we welcome them to White City. Their move is another sign that White City is becoming a vibrant and exciting life sciences cluster. There are unprecedented opportunities for academia, businesses and entrepreneurs in White City as our campus provides strength and leadership in molecular sciences, bioengineering and public health and close proximity to our medical research and translation work at Hammersmith Hospital. Imperial and Novartis’ proximity will enhance our collaboration as we work together to tackle healthcare challenges of our time”.
In further confirmation of the Novartis commitment to the UK, the company today confirmed it will expand its Biome programme to the UK. The Novartis Biome is a digital innovation lab that aims to empower and engender health tech companies and people passionate about disrupting healthcare through the use of data and digital technologies. The Novartis Biome is being built for entrepreneurs with a shared passion to innovate healthcare by solving real-world problems. It is intended to open up access to key Novartis resources, including relevant datasets, mentorship and customised curriculums.
The launch of the UK Biome and move to White City comes after a report by European Economics revealed the significant contribution that Novartis makes to the UK. According to the report, Novartis makes a £1.6bn contribution to the UK economy, including £592m in tax for public spending5. Sandoz, a division of Novartis that makes generic medicines and biosimilars, contributes cost savings for the NHS of £1.98billion each year. Novartis has 288 active collaborations with UK academic institutions across 17 therapy areas and contributes seven-times the industry average to NHS Joint Working Partnerships.
NOTES TO EDITORS
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death worldwide6. ASCVD results from a thickening and loss of elasticity in the arterial wall. It is a severe disorder and the leading cause of morbidity (sickness) and mortality (death) in most developed countries7. High levels of LDL cholesterol build up on the walls of blood vessels. This build up is called “plaque.” As blood vessels build up plaque over time, the insides of the vessels narrow. This narrowing blocks blood flow to and from the heart and other organs and eventually leads to heart disease or stroke8.
Inclisiran, potentially the first cholesterol-lowering therapy in the siRNA (small-interfering RNA) class, is an investigational twice-yearly therapy following initial and three-month doses in Phase III clinical development. As a siRNA, inclisiran harnesses the body’s process of RNA interference to specifically prevent production of a specific protein in the liver, which enhances the liver’s ability to remove LDL-C from the bloodstream, thereby lowering LDL-C levels9,10,11. Inclisiran is not yet approved by the FDA or any other regulatory authority. Novartis has global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement with Alnylam Pharmaceuticals.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
In 2018, Novartis supported a total of 17,458 UK jobs, of which it directly employed 1,268 full time equivalent workers to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is the single largest industry sponsor of clinical trials in the UK. For more information, please visit www.novartis.co.uk